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In vitro production of interleukin.1 receptor antagonist in chronic renal
failure, CAPD and HD. Dialysis-related symptoms are believed to be
mediated, at least in part, by monocyte/macrophage-derived pro-in-
flammatory cytokines including interleukin-l (IL-i) and tumor necrosis
factor (TNF). Measuring the production of interleukin-1 receptor an-
tagonist (IL-Ra), a naturally occurring inhibitor of IL-i, opens avenues
to study the balance between these two cytokines in patients. We
studied the cell content and production of IL-l/3 and IL-Ra by unstim-
ulated and endotoxin- or lgG-stimulated peripheral blood mononuclear
cells (PBMC) in undialyzed patients with chronic renal failure (CRF),
patients on continuous ambulatory pentoneal dialysis (CAPD) and
patients on chronic hemodialysis with reuse cuprophan membranes
(HD), and compared them to healthy controls. IL-1f3 and IL-Ra were
measured by specific radioimmunoassay. IL-1f3 was undetectable in
freshly harvested PBMC from healthy controls, CRF, CAPD or HD. In
contrast, the content of IL-Ra in HD patients (2828 466 pg/ml) was
significantly higher than that in healthy controls (643 53 pg/mI, P <
0.01), CRF (1097 320 pg/mI, P < 0.01) or CAPD (1398 390 pg/ml,P < 0.05). In endotoxin-stimulated PBMC, IL-l/3 production by HD
patients (9375 1687 pg/ml) was not significantly different from healthy
controls (8429 1621 pglml). However, endotoxin-stimulated IL-Ra
production by HD patients (32350 8276 pg/mI) was greater than that
from healthy controls (11284 1250 pg/ml, P < 0.001), CRF (12263
2680 pg/mI, P < 0.01) or CAPD patients (11822 1797 pg/mI, P <0.01).
In PBMC from healthy subjects, lgG and endotoxin induced similar
amounts of IL-Ra (15117 3507 pg/mI and 11284 1250 pg/mI,
respectively). In contrast, IgG-stimulated IL-Ra production was signif-
icantly lower than that induced by endotoxin in patients with CRF (6312
1907 pg/ml vs. 12263 2680 pg/ml, P < 0.0001), CAPD (7906 3239
pg/mlvs. 11822 l797pg/ml,P<0.0001)andHD(15642 7181 pg/mI
vs. 32350 8276 pg/ml, P < 0.0008). The relatively low levels of IL-Ra
produced by uremic PBMC in response to IgG is consistent with
defective Fc receptor number and/or function in patients with chronic
renal failure. The present study demonstrates heightened production of
IL-Ra in HD patients and suggests that IL-Ra may be a better indicator
of host inflammatory response during HD than IL-i.
Despite advances in technology, patients on hemodialysis
still experience substantial short and long-term dialysis-related
morbidity [1—6]. Dialysis-related symptoms, including, fever,
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hypotension, lassitude, nausea, and myalgias have been re-
ported in 55% to 95% of patients over a five month period [1].
In addition, dialysis patients suffer debilitating long-term com-
plications such as anorexia, malnutrition, osteopenia, increased
atherogenesis, and 132microglobulin-induced amyloidosis [7—9].
These acute and chronic dialysis-related symptoms are believed
to be mediated, at least in part, by monocyte/macrophage-
derived pro-inflammatory cytokines including interleukin- 113
(IL-l/3) and tumor necrosis factor (TNF) [10—12]. In some
studies, chronic hemodialysis patients have been shown to have
increased plasma levels of IL-1f3, TNF, and IL-6, whereas
other studies have shown that peripheral blood mononuclear
cells (PBMC) are "primed" to produce increased levels of
IL-1f3 upon stimulation in vitro [13—15]. Further, IL-lj3 mRNA
is expressed in PBMC within five minutes after exposure to
complement-activating hemodialysis membranes [16].
Naturally-occurring cytokine-specific inhibitory substances
have been described which may play a role in modulating the
inflammatory response [17—19]. An endogenous IL-l inhibitor
was observed in the circulation of human volunteers injected
with endotoxin [20]. A similar IL-i-specific inhibitory activity
was also observed in plasma from patients on chronic hemodi-
alysis, and the level was higher than that in healthy blood
donors [21]. The IL-i "inhibitor" was purified from the urine
and shown to block the binding of IL-i to its cell receptor [17].
Recently the IL-l inhibitor has been cloned, characterized and
renamed IL- 1 receptor antagonist (IL-Ra) [181. In a variety of
diseases, IL-Ra production is an indicator of host response to
local or systemic inflammation [22, 23]. These studies on IL-Ra
production have opened new avenues to study the balance
between IL- 1 and IL-Ra production in patients with chronic
renal failure, on chronic hemodialysis and chronic ambulatory
peritoneal dialysis. It is conceivable that the effects of chronic
IL-l production in hemodialysis patients might be reduced by
equivalent or excessive IL-Ra production. Alternatively, IL-Ra
production might be absent or deficient, thereby leading to
unopposed action of IL- 1. To examine these issues we studied
the production of IL-i f3 and IL-Ra by peripheral blood mono-
nuclear cells in patients with chronic renal disease prior to the
initiation of dialysis, and in patients on continuous ambulatory
peritoneal dialysis or chronic hemodialysis with reuse cu-
prophan membranes.
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Patients and controls. The study protocol was approved by
the Human Investigation Review Committees of The New
England Medical Center and St. Elizabeth's Hospital. Informed
consent was obtained from each participant. Twenty-five pa-
tients with chronic renal failure between 20 to 80 years of age
were included in the study, Of these, eight were undialyzed
patients with chronic renal disease (CRF, estimated GFR <10
ml/min), nine patients were on chronic ambulatory peritoneal
dialysis (CAPD) and eight patients were on chronic hemodial-
ysis (HD). The patients were dialyzed three times a week with
reuse cuprophan membranes (Clirans C081, Terumo corpora-
tion, Tokyo, Japan) and bicarbonate dialysate. To serve as
controls, twelve healthy volunteers, 20 to 50 years of age and
taking no medications, were recruited from our laboratory
personnel. Patients with acute infection or blood transfusion in
the past month, chronic infections (hepatitis B, hepatitis C,
human immunodeficiency virus, etc.), active immunological
disease (systemic lupus erythematosus, rheumatoid arthritis),
immunosuppressive therapy and malignancy were excluded
from participation in the study.
Laboratory methods
Blood collection. In patients on hemodialysis, 10 ml of blood
was drawn into a heparinized syringe, from the fistula needle
immediately following venipuncture prior to a routine hemodi-
alysis session. In undialyzed patients with chronic renal failure
and patients on peritoneal dialysis, 10 ml of blood was drawn
from a peripheral vein at the time of venipuncture for routine
laboratory investigations. Blood was drawn from a peripheral
vein in healthy controls.
In vitro production of IL-I and IL-Ra by peripheral blood
mononuclear cells (PBMC). Water and tissue culture media
used in this study were subjected to ultrafiltration using a
polysuiphone hollow-fiber ultrafilter (F40, Fresenius, Bad
Homburg, Germany) to remove cytokine-inducing agents [24].
PBMC were harvested as previously described [25, 261. Briefly,
each 10 ml sample of blood was drawn into a heparinized (500
units) polypropylene syringe. The blood was then diluted with
10 ml of sterile pyrogen-free normal saline (Abbott Laborato-
ries, Rockford, Illinois, USA) and underlayered with 10 ml of
Ficoll-Hypaque. The tube was centrifuged at 450 g for 45
minutes at room temperature. The PBMC layer was harvested,
washed in saline and centrifuged at 400 g for 10 minutes. The
cells were washed in saline two additional times. The cells were
then resuspended in ultraffitered tissue culture medium (RPMI
1640, pH 7.4, Sigma Chemical Co, St Louis, Missouri, USA),
containing 10 mmol/liter L-glutamine, 24 mmollliter NaHCO3
(Mallinckrodt, Paris, Kentucky), 10 mmollliter HEPES (Sig-
ma), 100 U/mi penicillin and 100 g/ml streptomycin (Irvine
Scientific, Santa Ana, California, USA) [261. Cells were
counted using a standard hemocytometer and adjusted to 5 x
l06/ml and 0.5 ml of cells were aliquoted into 12 X 75 mm
polypropylene tubes.
One polypropylene tube received 0.5 ml RPM! and was
immediately frozen at —70°C for estimation of cell content of
cytokines at zero time (Time 0). PBMC in identical tubes were
stimulated by the addition of 0.5 ml of RPM! containing either
Normals CRF CAPD HD
Fig. 1. Cellular content of IL-I$ () and IL-Rn (U) in freshly har-
vested PBMC. IL-113 levels were not assayed in healthy controls, and
were below limit of detection in all other groups (dotted line, <160
pg/mI). * Cell content of IL-Ra in HD patients was significantly higher
than that in healthy controls (P < 0.01), CRF (P < 0.01) or CAPD
patients (P < 0.05). Cell content of IL-Ra in CRF and CAPD was not
significantly higher than healthy controls.
20 ng/mi endotoxin (Escherichia coil, serotype 055:B5, Sigma)
or 20 tg/m1 human immunoglobulin IgG (Gammagard, Hyland
Laboratories, Duarte, California, USA). RPM! was added as a
non-stimulated control. The tubes were then incubated upright
at 37°C. At the end of 24 hours, the three tubes were frozen at
—70°C. The cell suspensions were subjected to two additional
freeze-thaw cycles. Undiluted or diluted samples were added to
radioimmunoassay buffer (0.01 mol/liter phosphate-buffered
saline, pH 7.4, 0.25% bovine serum albumin and 0.05% sodium
azide) and total IL-i /3 and IL-Ra synthesis (cell-associated and
secreted) were measured by specific non-cross-reactive RIA
[25, 261. The IL-1/3 or IL-Ra concentrations were then read
from a logit plot of percent specific binding versus the log
concentration of a serially diluted IL-1f3 or IL-Ra from the
linear portion of the curve (usually between 35% and 85%
specific binding). The limits of detection of the IL-i /3 and IL-Ra
RIA were 160 pg/mi and 80 pg/mI, respectively.
Statistical analysis
Statistical analysis was performed using the Stat-view soft-
ware package (Abascus Concepts Inc., Calabasas, California,
USA). Two-tailed paired t-tests and analysis of variance
(ANOVA) using Fisher's least significant difference were em-
ployed. Data are expressed as mean standard error of the
mean (sEM). Differences were considered significant at <0.05.
Results
IL-Ra and IL-1f3 content in PBMC
As shown in Figure 1, IL-1/3 content in PBMC from healthy
controls, CRF, CAPD or HD patients (taken from the fistuia
needle before the start of HD) was below the limit of detection
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Normals CRF CAPD HD
Fig. 2. Production of IL-I 13 () and IL-Ra (LI) by unstimulated PBMC
cultured for 24 hours. * IL-1p production by CRF and CAPD patients
was significantly lower (P < 0.05) than healthy controls. ** IL-Ra
production by CRF and HD patients was significantly higher than
healthy controls (P < 0.05).
nI.1I.rI
Normals CRF CAPD HD
Fig. 3. Stimulation of IL-I 13 () and IL-Ra (LI) in PBMC by endotoxin.
* IL-l/3 production by CRF and CAPD patients was significantly lower
than healthy controls (P < 0.05) and HD patients (P < 0.01). ** IL-Ra
production in HD patients was significantly higher than healthy controls(P < 0.001), CRF (P < 0.01) or CAPD patients (P < 0.01). IL-Ra
production was significantly higher than IL-1J3 in CRF (P < 0.0005),
CAPD (P < 0.0001) and HD patients (P < 0.02).
(2828 466 pg/mi) was significantly higher than healthy con-
trols (643 53 pg/ml, P < 0.01), CRF (1097 320 pg/ml, P <
0.01) or CAPD patients (1398 390 pg/mI, P < 0.05).
Spontaneous production of IL-Ra and IL-I /3 by unstimulated
PBMC
After 24 hours of culture at 37°C, spontaneous IL-1/3 produc-
tion by CRF (<160 nglml) or CAPD (<160 ng/ml) patients was
significantly lower (P < 0.05) than that by healthy controls (337
62 pg/mI) (Fig. 2). IL-Ra production in HD (3063 1388
pg/ml) and CRF patients (3400 626 pg/mi) was significantly
higher (P < 0.05) than healthy controls (966 178 pg/mI). The
Fisher's test for the renal failure group as a whole did not reach
statistical significance (P < 0.07).
Production of IL-Ra and IL-1J3 by endotoxin-stimulated
PBMC
Endotoxin-stimulated IL-1f3 production by PBMC from HD
patients (9375 1687 pg/ml) was not significantly different from
healthy controls (8429 1621 pg/mi; Fig. 3). However, endo-
toxin-stimulated IL-1J3 production by PBMC from CRF patients
(3431 887 pg/mI) was significantly lower than both HD
patients (P < 0.01) and healthy controls (P < 0.05). Likewise,
endotoxin-stimulated IL-1/3 production by PBMC from CAPD
patients (4528 1010 pg/ml) was also significantly lower (P <
0.05) than both HD patients and healthy controls.
In contrast, endotoxin-stimulated IL-Ra production by
PBMC from HD patients (32350 8276 pg/mi) was significantly
higher than healthy controls (11284 1250 pg/ml, P < 0.001),
CRF (12263 2680 pg/mI, P < 0.01) or CAPD patients (11822
1797 pg/mI, P <0.01; Fig. 3).
In PBMC from healthy controls, endotoxin stimulated ap-
proximately equivalent amounts of IL-Ra and IL- 1/3 (11284
1250 pg/mI vs. 8429 1621 pg/mi, respectively). On the other
hand, IL-Ra production by PBMC from HD patients was
Normals CRF CAPD HD
Fig. 4. Stimulation of IL-i 13 () and IL-Ra (LI) in PBMC by IgG. IgG
does not stimulate IL- 113 production. IL-Ra production was not signif-
icantly different among groups.
threefold higher (32350 8276 pg/ml) than IL-l/3 (9375 1687
pg/ml, P < 0.02). Similarly, IL-Ra was significantly higher than
IL-1$ production in CRF (12262 2680 pg/mi vs. 3431 887
pg/mi, P < 0.0005) and CAPD patients (11822 1797 pg/ml vs.
4528 1010 pg/ml, P < 0.0001).
Production of IL-Ra by IgG-stimulated PBMC
IgG had little stimulatory effect on IL-1/3 production in all
four groups (Fig. 4), which was consistent with previous
findings [25]. As shown in Figure 4, IgG-stimulated IL-Ra
production by PBMC from healthy controls (15117 3507
pg/mi) was not significantly different from HD patients (15642
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Normals CRF CAPD HD
Fig. 5. Ratio of IgG:endotoxin-stirnulated production of IL-Ra by
PBMC. IgG:endotoxin stimulated IL-Ra production in healthy controls
was significantly higher than that in CRF (P < 0.05), CAPD (P < 0.007)
or HD patients (P < 0.005).
controls and HD patients were higher than that in CRF (6313
1907 pg/mi) or CAPD (7906 3239 pg/mi) patients, the Fisher's
test for comparisons between groups did not reach statistical
significance.
Relative production of IL-Ra by IgG-srimulated PBMC versus
endotoxin-stirnulated PBMC
At 10 rg/ml, IgG is a potent stimulus for IL-Ra production in
healthy controls [25], achieving levels (15117 3507 pg/mi)
which were not significantly different (P > 0.05) from 10 ng/ml
of endotoxin-stimulated IL-Ra production (11284 1250 pg/
ml). In contrast, IgG-stimulated IL-Ra production was signifi-
cantly lower than that by endotoxin-stimulated PBMC in CRF
(6312 1907 pg/mi vs. 12263 2680 pg/mi, P < 0.0001), CAPD
(7906 3239 pg/mI vs. 11822 1797 pg/mi, P < 0.000 1) and HD
(15642 7181 pg/mI vs. 32350 8276 pg/mi, P < 0.0008). As
shown in Figure 5, the ratio of IgG:endotoxin-stimulated IL-Ra
production in healthy controls (1.6 0.3) was significantly
higher than that in CRF (0.8 0.1, P < 0.05), CAPD (0.6 0.1,
P < 0.007) or HD patients (0.5 0.2, P < 0.005).
Discussion
As recently reviewed [22, 27, 28], IL-Ra is a 17 Kd poiypep-
tide which shows 41% conserved homology to IL-1f3 (30% to
IL-la). On the type I IL-i receptor (IL-1R), IL-Ra has nearly
the same affinity as IL-la or IL-1f3, but lacks agonist activity.
IL-Ra competitively binds to IL-1R, preventing IL-i binding
and consequently the biological responses to IL-i [22, 27, 28].
During infection and inflammation both IL-i and its inhibitor
are produced [23, 291. To investigate the production of IL-i$
and IL-Ra in patients with untreated CRF (before initiation of
dialysis), patients on CAPD and chronic HD with reuse cu-
prophan membranes, we studied the production of these cyto-
kines by PBMC in vitro, under different stimulatory conditions.
Our results showed: (1) in patients on HD, content of IL-Ra in
freshly obtained PBMC was higher than in patients with CRF,
CAPD patients or healthy controls; (2) production of IL-Ra by
endotoxin-stimulated IL-Ra production by PBMC from HD
patients was threefold higher than patients with CRF, CAPD
patients or healthy controls; (3) endotoxin-stimulated PBMC
from all three groups of patients with renal failure produced
significantly more IL-Ra then IL-1f3; and (4) IgG was a less
potent stimulus of IL-Ra production than endotoxin in PBMC
from all three groups of patients with renal failure.
During hemodialysis, human blood leukocytes come into
contact with three exogenous challenges: the surface material
of the dialyzer membrane, plasma products activated by the
dialyzer materials and substances (solutes and microbial prod-
ucts) from the dialysis bath. These interactions can trigger
synthesis of mononuclear cell products, such as the pro-
inflammatory cytokines, IL-i and tumor necrosis factor [re-
viewed in 30]. Indeed, others have shown that during dialysis
new gene expression for cytokines occurs [161, intracellular
content of IL-I is elevated [31], and plasma levels of cytokines
are increased following dialysis [32]. These cytokines have been
implicated as the cause of several dialysis-related symptoms
[10, 11, 30]. To date, the effects of HD on the production of
IL-Ra have not been examined. Our data demonstrate that in
patients on chronic HD, IL-Ra production by PBMC is in-
creased. However, biological responses to IL-i can be induced
by occupancy of as little as 5% of IL-i receptors, and a 10 to 100
molar excess of IL-Ra is required to inhibit 50% of IL-i induced
responses in vitro [22, 27, 28]. Therefore, it is unclear whether
the elevated levels of IL-Ra observed in HD patients are high
enough to reduce the biological effects of IL-i induced during
hemodialysis.
The stimulus for the increased production of IL-Ra in hemo-
dialysis patients is unclear. It is likely that the production of
both IL-i /3 and IL-Ra are induced by the same stimuli that are
operative during hemodialysis. Human IgG is a potent stimulus
for IL-Ra production in PBMC in vitro, and concentrations as
low as 1 sg/ml induce significant production [25]. In healthy
volunteers we observed no differences in the IL-Ra production
induced by IgG as compared to endotoxin. In contrast, the
IgG-induced IL-Ra production in all three groups of patients
with renal failure was significantly lower than that of endotoxin-
induced production. These data suggest that the response to
IgG is impaired in uremic PBMC, which persists despite dialy-
sis. The mechanism for the stimulation of IL-Ra production by
IgG is probably via the Fc receptor [25]. Conditions that
augment Fc receptor expression and/or function such as GM-
CSF [33] also increase IgG-induced IL-Ra production [25].
Therefore, the relatively low levels of IL-Ra produced by
uremic PBMC in response to IgG may be a consequence of
defective Fe receptor number and/or function in patients with
chronic renal failure. Indeed, Ruiz, Gomez and Schreiber have
demonstrated that the clearance of IgG coated red blood cells is
impaired in patients with chronic renal disease [34], a process
which is mediated by Fe receptors on splenic macrophages
[35—381. In addition, these authors observed defective binding
of IgG coated red cells by PBMC from uremic patients [34].
These data and our observations are consistent with a defect in
the Fe receptor on PBMC in uremic patients, which is not
corrected by dialysis.
IL-i appears to have a role in specific and non-specific
immune responses. Similar to other cells, IL-i receptors are
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T and B cell activation [22, 39]. IL-i added to lymphocyte
cultures enhances proliferative responses, and IL-i acts as an
adjuvant during immunization [27]. IL-i also has been shown to
amplify T cells by inducing IL-2 and IL-2 receptor gene
expression. Further, IL-l increases gene expression of IL-4,
IL-6, IL-7 and GM-CSF, which are known to be "lymphocyte
activating factors" [22]. The enhanced IL-Ra production in HD
patients raises the possibility that the immunosuppressive ef-
fects of uremia [34, 40—43] may be compounded by the in-
creased production of IL-Ra in these patients. Whether in-
creased IL-Ra production causes immunosuppression remains
unclear [22, 27]. Although a 10- to 100-fold excess of IL-Ra
inhibits IL-i-induced physiological responses in vitro by ap-
proximately 50% [22], a twofold molar excess of IL-Ra is
capable of reducing IL- i-induced IL-i, IL-6, IL-8 or TNF
production in vitro by human PBMC by 50% [44, 45]. However,
IL-Ra does not inhibit the proliferative response of peripheral
blood lymphocytes to mitogens or the mixed lymphocyte reac-
tion [46]. Therefore, the effects of the heightened IL-Ra pro-
duction on the immunological competence in uremic patients
remains unresolved.
In the present study we observed a defect in IL-1f3 produc-
tion by PBMC from undialyzed CRF and CAPD patients. IL-1/3
production by unstimulated and endotoxin-stimulated PBMC
from undialyzed CRF and CAPD patients was significantly
lower than that of normal controls. A decreased cell-associated
IL-i activity in uremic monocytes has also been reported by
others [31]. This may be a part of the multiple derangements in
the immunological repertoire in uremia [34, 40—43]. In other
studies, IL-i production by unstimulated monocytes from
blood drawn before dialysis has been reported to be normal by
some [14] and elevated by others [31, 47]. Our observations
suggest that uremia may result in reduced IL-i production by
PB MC, but that hemodialysis masks this reduction by "prim-
ing" these cells to produce more IL-1f3 and IL-Ra.
The "Interleukin Hypothesis" proposes that pro-inflamma-
tory cytokines may be responsible for a variety of dialysis-
related complications [10, 11]. Our data indicate that patients on
chronic hemodialysis have a heightened production of IL-Ra in
unstimulated and stimulated PBMC. This may reflect a height-
ened host response to inflammation, presumably from the HD
procedure. Whether this elevated production of IL-Ra is suffi-
cient to overcome the effect of IL-l is as yet unclear. Indeed, in
vitro studies suggest that a substantial molar excess of IL-Ra is
required to overcome the effects of IL- 1, raising the possibility
that the threefold higher IL-Ra response in HD patients may be
suboptimal in some patients. On the other hand, the present
results suggest that the increased production of IL-Ra by
PBMC from HD patients is a better indicator of the host
response to the cytokine-inducing stimuli encountered during
hemodialysis than IL-l.
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